Phase II trial of mitoxantrone in head and neck cancer

Matti S. Aapro, Davis S. Alberts

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Mitoxantrone (1,4-dihydroxy-5,8-bis((2-[(2-hydroxyethyl)amino]ethyl)amino)-9, 10 anthracenedione dihydrochloride, NSC 301,739) is a new aminoanthraquinone derivative with clinical activity in the treatment of advanced breast cancer (1, 2), lymphoma (3), and acute leukemia (4). We have carried out a phase II trial of mitoxantrone using an every three weeks dosing schedule in patients with advanced head and neck cancers.

Original languageEnglish (US)
Pages (from-to)329-330
Number of pages2
JournalInvestigational New Drugs
Issue number3
StatePublished - Sep 1984


  • head and neck cancer
  • mitoxantone

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Phase II trial of mitoxantrone in head and neck cancer'. Together they form a unique fingerprint.

Cite this